DEF: Veru Inc. Seeks Shareholder Approval for Equity Plan Expansion

Veru Inc. is calling its shareholders to an Annual Meeting on March 12, 2026, to vote on key proposals including the election of directors, auditor ratification, and a significant amendment to its equity incentive plan.

Summary

• An Annual Meeting of Shareholders is scheduled for March 12, 2026, to address five key proposals.
• Proposals include the election of six directors, ratification of Cherry Bekaert LLP as the independent auditor for fiscal year 2026, and a non-binding advisory vote on executive compensation.
• A significant proposal seeks to amend the 2018 Equity Incentive Plan, increasing authorized shares from 2,600,000 to 5,850,000, and raising annual award limits for participants and non-employee directors.
• The company reported a net loss of $(22,726) thousand in fiscal 2025, an improvement from $(37,801) thousand in 2024 and $(93,153) thousand in 2023.
• Total Shareholder Return (TSR) for a $100 investment declined to $3.30 by the end of fiscal 2025, from $6.68 in 2024 and $6.25 in 2023.
• The company's previous auditor, RSM US LLP, included a "going concern" explanatory paragraph in its report for fiscal year 2023.
• Material weaknesses in internal control over financial reporting were identified in fiscal years 2023 and 2024, leading to restatements.
• The proposed amendment to the equity plan would increase the fully-diluted overhang (potential dilution) from 7.4% to 13.9%.
• The weighted average exercise price of outstanding options and stock appreciation rights is $35.77, significantly above the Common Stock's last reported sale price of $2.34 as of January 14, 2026.

Sentiment

Score: 3

Explanation: The company faces significant challenges, including a 'going concern' note from its previous auditor, persistent net losses, and a substantial decline in Total Shareholder Return. While net losses are decreasing, the proposed equity plan amendment, which would significantly increase dilution, and the large number of underwater stock options, indicate underlying issues with shareholder value creation and executive incentives. The material weaknesses in internal controls also raise concerns about financial reporting reliability.

Positives

• Net loss has significantly decreased from $(93,153) thousand in fiscal 2023 to $(22,726) thousand in fiscal 2025.
• The company maintains a commitment to high standards of corporate governance, including independent board committees and a Code of Business Ethics.
• Executive compensation program is described as clear, straightforward, and performance-based, with no perquisites or supplemental retirement benefits.
• A Compensation Clawback Policy was adopted effective November 30, 2023, aligning with SEC requirements for accounting restatements.
• The 2018 Equity Incentive Plan includes shareholder-focused features such as a fixed maximum number of authorized shares, minimum 12-month vesting periods (with exceptions), and prohibitions against repricing stock options.

Negatives

• Total Shareholder Return (TSR) has seen a substantial decline, with an initial $100 investment on September 30, 2022, valued at only $3.30 by September 30, 2025.
• The previous independent auditor, RSM US LLP, issued an explanatory paragraph in its fiscal year 2023 report indicating "substantial doubt about the Company's ability to continue as a going concern."
• Material weaknesses in internal control over financial reporting were identified in fiscal years 2023 and 2024, leading to restatements of financial statements.
• The weighted average exercise price of outstanding stock options and stock appreciation rights is $35.77, which is approximately 1528% of the Common Stock's last reported sale price of $2.34 as of January 14, 2026, indicating a large number of underwater options.
• The proposed amendment to the 2018 Equity Incentive Plan would increase potential shareholder dilution (overhang) from 7.4% to 13.9% on a fully-diluted basis.
• The Chief Executive Officer also serves as Chairman of the Board, which may raise concerns about board independence for some governance advocates.
• A related party transaction involved the son of Dr. Harry Fisch (Vice Chairman and Chief Corporate Officer) receiving $296,000 in total compensation in fiscal 2025.

Risks

• Substantial doubt about the Company's ability to continue as a going concern, as noted by the previous auditor for fiscal year 2023.
• Material weaknesses in internal control over financial reporting, specifically related to applying technical accounting guidance to nonrecurring events and transactions, and management review control over research and development expenses.
• Potential inability to attract, motivate, and retain high-quality executives and employees if the proposed amendment to the 2018 Equity Incentive Plan is not approved, potentially leading to reliance on less efficient cash-based compensation.
• Dilutive impact on shareholders from the issuance of additional shares under the equity compensation program.
• The majority of outstanding stock options are significantly "underwater" (exercise price of $35.77 vs. stock price of $2.34), potentially reducing their effectiveness as an incentive.

Future Outlook

The company emphasizes that amending its 2018 Equity Incentive Plan is critically important for attracting, motivating, and retaining high-quality executives and employees, which are essential for its future success. Management believes that equity-based awards are more effective in aligning employee interests with shareholders compared to potential alternative cash or non-equity rewards, which would also deplete cash resources more quickly.

Management Comments

• "We believe that the amendment to the 2018 Equity Incentive Plan is critically important to the furtherance of these objectives [attracting, retaining, motivating key personnel and aligning interests with shareholders]."
• "We believe that such alternative forms of compensation [cash and non-equity rewards if equity plan not approved] do not align employee interests with those of shareholders as efficiently as equity-based awards, and we feel it is important to provide compensation that continues to effectively align employees with shareholders and which provides a total compensation package that is competitive with other companies."

Industry Context

The company operates in highly competitive labor markets, particularly within the pharmaceutical and drug development industries, necessitating robust equity compensation programs to attract and retain skilled talent. The proposed expansion of the equity incentive plan is framed as a response to this competitive environment and a means to maintain a competitive total compensation package.

Comparison to Industry Standards

• The company states it aims to provide a total compensation package that is competitive with other companies, but it does not provide specific comparable companies, projects, or results for benchmarking.

Management Changes

Corporate Governance

Related Party Transactions

• The son of Dr. Harry Fisch, Vice Chairman and Chief Corporate Officer, is employed by the Company in a non-executive officer position and earned $296,000 in total compensation for fiscal 2025.

Stakeholder Impact

• Shareholders: Potential dilution from the proposed increase in authorized shares for the equity incentive plan (overhang increasing from 7.4% to 13.9%). Risk of continued poor Total Shareholder Return. Opportunity to vote on key governance matters and executive compensation.
• Employees/Executives: The proposed equity plan amendment is intended to attract, motivate, and retain high-quality personnel by providing equity opportunities and performance-based incentives. Existing stock options are largely underwater, potentially impacting morale and retention.
• Auditors: Cherry Bekaert LLP's appointment is subject to shareholder ratification. RSM US LLP was dismissed due to material weaknesses in internal controls.

Next Steps

• Shareholders to vote on the election of six directors at the Annual Meeting on March 12, 2026.
• Shareholders to vote on the ratification of Cherry Bekaert LLP as the independent registered public accounting firm for fiscal year ending September 30, 2026.
• Shareholders to vote on the amendment to the 2018 Equity Incentive Plan.
• Shareholders to cast a non-binding advisory vote on executive compensation.
• Shareholders to vote on a proposal to approve the adjournment of the Annual Meeting if necessary.
• The Compensation Committee will take into account the outcome of the non-binding advisory vote on executive compensation when considering future arrangements.
• The Audit Committee will reconsider the appointment of Cherry Bekaert LLP if ratification is not obtained, and may appoint another firm.

Key Dates

Recommendation

The filing reveals several significant red flags for investors, including a 'going concern' explanatory paragraph from the previous auditor for fiscal year 2023, persistent material weaknesses in internal financial controls leading to restatements, and a drastic decline in Total Shareholder Return (TSR) where a $100 investment is now worth only $3.30. Furthermore, the proposed amendment to the equity incentive plan, while framed as necessary for talent retention, would significantly increase potential shareholder dilution (overhang from 7.4% to 13.9%) at a time when the vast majority of existing stock options are deeply 'underwater' (average exercise price of $35.77 vs. current stock price of $2.34). This combination of severe financial distress, governance issues, and proposed dilution without clear evidence of improved shareholder value creation warrants a 'sell' recommendation.

Keywords

Veru Inc., Proxy Statement, Shareholder Meeting, Equity Incentive Plan, Executive Compensation, Corporate Governance, Auditor Ratification, Stock Options, Dilution, Going Concern, Internal Controls, Biotechnology, Pharmaceuticals